These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 12734315)

  • 1. Development of investigational radiation modifiers.
    Colevas AD; Brown JM; Hahn S; Mitchell J; Camphausen K; Coleman CN;
    J Natl Cancer Inst; 2003 May; 95(9):646-51. PubMed ID: 12734315
    [No Abstract]   [Full Text] [Related]  

  • 2. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?
    Gelmon KA; Eisenhauer EA; Harris AL; Ratain MJ; Workman P
    J Natl Cancer Inst; 1999 Aug; 91(15):1281-7. PubMed ID: 10433616
    [No Abstract]   [Full Text] [Related]  

  • 3. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.
    Lawrence YR; Vikram B; Dignam JJ; Chakravarti A; Machtay M; Freidlin B; Takebe N; Curran WJ; Bentzen SM; Okunieff P; Coleman CN; Dicker AP
    J Natl Cancer Inst; 2013 Jan; 105(1):11-24. PubMed ID: 23231975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitizers and protectors of radiation and chemotherapy.
    Poggi MM; Coleman CN; Mitchell JB
    Curr Probl Cancer; 2001; 25(6):334-411. PubMed ID: 11740469
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of the National Cancer Institute in drug development.
    Doroshow J
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
    [No Abstract]   [Full Text] [Related]  

  • 6. Slow start to phase 0 as researchers debate value.
    Twombly R
    J Natl Cancer Inst; 2006 Jun; 98(12):804-6. PubMed ID: 16788150
    [No Abstract]   [Full Text] [Related]  

  • 7. For investigational targeted drugs, combination trials pose challenges.
    Goldman B
    J Natl Cancer Inst; 2003 Dec; 95(23):1744-6. PubMed ID: 14652234
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical development of anticancer agents--a National Cancer Institute perspective.
    Marsoni S; Wittes R
    Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
    [No Abstract]   [Full Text] [Related]  

  • 9. Sensitizers and protectors in clinical oncology.
    Phillips TL
    Semin Oncol; 1981 Mar; 8(1):65-82. PubMed ID: 6264627
    [No Abstract]   [Full Text] [Related]  

  • 10. How does a drug get to phase III trials?
    Reynolds T
    J Natl Cancer Inst; 2000 Oct; 92(19):1555. PubMed ID: 11018084
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of amifostine as a radioprotector.
    Wasserman TH; Brizel DM
    Oncology (Williston Park); 2001 Oct; 15(10):1349-54; discussion 1357-60. PubMed ID: 11702962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive design may hasten clinical trials.
    Schmidt C
    J Natl Cancer Inst; 2007 Jan; 99(2):108-9. PubMed ID: 17227993
    [No Abstract]   [Full Text] [Related]  

  • 13. Rapid reporting and review of an increased incidence of a known adverse event.
    Sargent DJ; Goldberg RM; Mahoney MR; Hillman DW; McKeough T; Hamilton SF; Darcy JM; Anderson VL; Krook JE; O'Connell MJ
    J Natl Cancer Inst; 2000 Jun; 92(12):1011-3. PubMed ID: 10861314
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel agents in colorectal cancer.
    Erlichman C
    Tumori; 2001; 87(1 Suppl 1):S9. PubMed ID: 11300041
    [No Abstract]   [Full Text] [Related]  

  • 15. Multidrug resistance: can new drugs help chemotherapy score against cancer?
    Goldman B
    J Natl Cancer Inst; 2003 Feb; 95(4):255-7. PubMed ID: 12591977
    [No Abstract]   [Full Text] [Related]  

  • 16. Oncology's first Phase 0 trial.
    Rowan K
    J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
    [No Abstract]   [Full Text] [Related]  

  • 17. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers.
    Harrington KJ; Billingham LJ; Brunner TB; Burnet NG; Chan CS; Hoskin P; Mackay RI; Maughan TS; Macdougall J; McKenna WG; Nutting CM; Oliver A; Plummer R; Stratford IJ; Illidge T
    Br J Cancer; 2011 Aug; 105(5):628-39. PubMed ID: 21772330
    [No Abstract]   [Full Text] [Related]  

  • 18. Search for new radiation potentiators.
    Goldin A; Wodinsky I; Merker PC; Venditti JM
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):25-35. PubMed ID: 632145
    [No Abstract]   [Full Text] [Related]  

  • 19. Accessing investigational anticancer agents outside of clinical trials.
    Montello MJ; Greenblatt JJ; Fallavollita A; Shoemaker D
    Am J Health Syst Pharm; 1998 Apr; 55(7):651-2, 660. PubMed ID: 9558419
    [No Abstract]   [Full Text] [Related]  

  • 20. Learning from exceptional drug responders.
    Mullard A
    Nat Rev Drug Discov; 2014 Jun; 13(6):401-2. PubMed ID: 24875081
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.